Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Anemia, Chronic Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more

Conditions: Anemia
Interventions: ferumoxytol or placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 41
States / cities: Mobile, Alabama • Phoenix, Arizona • Mountain View, California + 36 more

Conditions: Uterine Hemorrhage, Contraception
Interventions: Combined Oral Contraceptive Pill, Placebo Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Opiate Withdrawal Syndrome, Opioid Use
Interventions: LFX/PGB, LFX/PLA-PGB; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Sensoril®, Placebo; Drug
Lead sponsor: K.N. Roy Chengappa; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, Depression
Interventions: Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH), Sham Whole-Body Hyperthermia (Sham WBH); Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Female Hormone Profile
Interventions: Vitamin D (Cholecalciferol ), Placebo Group; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions: Mesenchymal Stem Cells, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions: T92, Placebo; Dietary Supplement
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dermatomyositis
Interventions: human immunoglobulin G, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: Healthy Adult Premenopausal Female Volunteers
Interventions: ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy
Interventions: Selpercatinib, Moxifloxacin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Smoking, Cigarette, Breastfeeding
Interventions: Integrated intervention of smoking cessation and breastfeeding, Attention placebo control; Behavioral
Lead sponsor: Xiaozhong Wen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Vitamin D Deficiency
Interventions: 400 IU Vitamin D3 (cholecalciferol), 2400 IU Vitamin D3 (cholecalciferol), 6400 IU Vitamin D3 (cholecalciferol); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Rochester, New York • Charleston, South Carolina

Conditions: Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions: Lopinavir / ritonavir; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 22 Years to 50 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more

Conditions: HIV Infections
Interventions: SAV001-H; Biological
Lead sponsor: Sumagen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions: RM-131, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more

Conditions: IgG4 Related Disease
Interventions: Inebilizumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: Lassa Fever, Lassa Virus Infection
Interventions: rVSV∆G-LASV-GPC, Placebo/Diluent; Drug · Other
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Brookline, Massachusetts

Conditions: Nicotine Dependence
Interventions: NIC002 in Aluminum hydroxide (Alum), Placebo Vaccine - Aluminum hydroxide; Biological
Lead sponsor: Alexey Mukhin; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Durham, North Carolina • Winston-Salem, North Carolina

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoarthritis, Knee
Interventions: acupuncture; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Search by objective public record fields.

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Crossover Safety Study of Ferumoxytol Versus Placebo

Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2

Acute Vitamin D Supplementation on Testosterone in Females

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding

Establishing the Vitamin D Requirements During Lactation

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Improving the Efficacy of Anti-Nicotine Immunotherapy

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

An Acupuncture Functional Magnetic Resonance Imaging (fMRI) Study on Chronic Pain: Response Reliability and Dose Effect